Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain After Total Knee Arthroplasty
Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain on the First Post-operative Day After Total Knee Arthroplasty
연구 개요
상세 설명
Patients will be included on the first day after TKA surgery and randomized in two groups. Each group will receive 2 ACB with a 1 hour interval, one ACB with an active drug, Ropivacaine, and another ACB with a placebo drug, Saline.
At T0, arm ACB_active/placebo will receive the active ACB with Ropivacaine followed by the placebo ACB at T60 (60 minutes after T0).
At T0, arm ACB_placebo/active will receive the placebo ACB with Saline followed by the active ACB with Ropivacaine at T60 (60 minutes after T0).
Outcome measurements will be made at T60, 1 hour after the first ACB, and the difference in outcome between the groups will be compared.
Baseline values will be measured prior to the first ACB. Final measurements at T120 (120 minutes after the initial ACB), will determine if the differences between the groups are eliminated, since both groups then have received an active ACB.
연구 유형
등록 (실제)
단계
- 4단계
연락처 및 위치
연구 장소
-
-
-
Hellerup, 덴마크, 2900
- Gentofte Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients who have had a Total Knee Arthroplasty surgery within 2 days (1.postoperative day on inclusion)
- Written informed consent.
- ASA 1-3
Exclusion Criteria:
- Non-cooperative patients
- Patients who have already had a peripheral or central block post surgery.
- Patients who are not able to perform a TUG test pre surgery.
- Patients who do not understand or speak Danish.
- Patient who are allergic to the drugs used in this research.
- Patients with alcohol- or drug abuse - determined by investigator.
- Patients with peripheral sensory neuropathy in their lower extremities.
- Pregnant patients.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: ACB_active/placebo
Patients will receive the first ACB with a active drug, 30 ml bolus Ropivacaine 7,5 mg/ml at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60 (60 minutes after T0), patients will receive their second ACB with the placebo drug, 30 ml bolus Saline and outcome measures performed again at T120(120 minutes after T0). The measurements for baseline and outcome will be made in following order: VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test |
다른 이름들:
다른 이름들:
|
|
위약 비교기: ACB_placebo/active
Patients will receive the first ACB with placebo, 30 ml isotonic saline at T0. First outcome measurement are made one hour after the first ACB, prior to their second ACB. At T60(60 minutes after T0), patients will receive their second ACB with the ropivacaine 7,5 mg/ml 30 ml and outcome measures performed again at T120(120 minutes after T0). The measurements for baseline and outcome will be made in following order: VAS pain score at rest - VAS pain score during active flexion of the knee - Muscle strength - TUG test - Highest VAS pain score during TUG test |
다른 이름들:
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference between groups in muscle strength of the quadriceps femoris muscle.
기간: 60 minutes after first ACB (T60)
|
Muscle strength is assessed as maximum voluntary isometric contraction (MVIC) using a hand-held dynamometer.3
consecutive measurements will be made and the average used.
Results for each group will be presented as percentage of baseline values.
The primary outcome is the difference in MVIC between the groups.
|
60 minutes after first ACB (T60)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference between groups in muscle strength of the quadriceps femoris muscle.
기간: 120 minutes after initial ACB (T120)
|
Same as primary outcome
|
120 minutes after initial ACB (T120)
|
|
VAS pain scores at rest
기간: 60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120)
|
Pain at rest (VAS 0-100 mm) one hour after the first and second ACB. Results will be compared between the two groups. VAS pain scores at rest will be inquired before any other outcome measurements. |
60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120)
|
|
VAS pain score during TUG test.
기간: 60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
Highest VAS (0-100 mm) pain score during TUG test will be inquired for each TUG test.
Results will be compared between the two groups.
|
60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
|
Timed Up and Go(TUG) test
기간: 60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
Time (seconds) to complete a TUG test measured one hour after the first and second ACB.
Results will be compared between the two groups.
|
60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
|
VAS pain scores during 45 degrees active flexion of the knee
기간: 60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
Specification of pain (VAS 0-100 mm) during 45 degrees active flexion of the knee one hour after first and second ACB.
Results will be compared between the two groups.
|
60 minutes after the initial ACB (T60) and 120 minutes after initial ACB (T120
|
|
Sub-group analysis of muscle strength and mobility acconding to baseline VAS during active flexion of the knee prior to the first block
기간: 60 minutes after first ACB (T60)
|
According to their specified VAS (0-100 mm) pain score during active flexion of the knee prior to the first block, patients will be divided into two groups.
Group 1 VAS 0-59 mm and group 2 with VAS 60-100 mm.
Results within the two groups will be compared: e.g is there a difference in MVIC in the subgroup of patients scoring VAS 0-59 during active knee flexion at baseline?
and is this difference larger in the subgroup of patients scoring VAS 60-100?
|
60 minutes after first ACB (T60)
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Ulrik Grevstad, MD, Gentofte Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2014-002245-21
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
식염에 대한 임상 시험
-
The Allergy and Asthma Institute, PakistanUniversity of Edinburgh모병코로나바이러스감염증-19 : 코로나19파키스탄
-
National Institute of Allergy and Infectious Diseases...완전한
-
Ionis Pharmaceuticals, Inc.빼는지리적 위축 | 연령 관련 황반 변성호주, 미국, 뉴질랜드
-
Umraniye Education and Research Hospital모병수술 후 메스꺼움 및 구토 | 복강경 위소매절제술 후 수술 후 통증터키 (Türkiye)
-
National Institute of Allergy and Infectious Diseases...완전한
-
Shanghai Argo Biopharmaceutical Co., Ltd.아직 모집하지 않음
-
Shanghai Argo Biopharmaceutical Co., Ltd.모병